These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Stehle S; Kirchheiner J; Lazar A; Fuhr U Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879 [TBL] [Abstract][Full Text] [Related]
6. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Sconce EA; Khan TI; Wynne HA; Avery P; Monkhouse L; King BP; Wood P; Kesteven P; Daly AK; Kamali F Blood; 2005 Oct; 106(7):2329-33. PubMed ID: 15947090 [TBL] [Abstract][Full Text] [Related]
7. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586 [TBL] [Abstract][Full Text] [Related]
8. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Miao L; Yang J; Huang C; Shen Z Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045 [TBL] [Abstract][Full Text] [Related]
9. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations. Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192 [TBL] [Abstract][Full Text] [Related]
10. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052 [TBL] [Abstract][Full Text] [Related]
12. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797 [TBL] [Abstract][Full Text] [Related]
13. [Warfarin resistance and related pharmacogenetic information]. Takahashi H Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171 [TBL] [Abstract][Full Text] [Related]
14. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498 [TBL] [Abstract][Full Text] [Related]
15. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB; Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891 [TBL] [Abstract][Full Text] [Related]
16. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Benusiglio PR; Desmeules J; de Moerloose P; Dayer P Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831 [TBL] [Abstract][Full Text] [Related]
17. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Scott SA; Edelmann L; Kornreich R; Desnick RJ Am J Hum Genet; 2008 Feb; 82(2):495-500. PubMed ID: 18252229 [TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356 [TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031 [TBL] [Abstract][Full Text] [Related]
20. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients. Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]